FindTrial
Sign In

A study to find out the effectiveness of measles, mumps, rubella(mmr) vaccine in the treatment of common warts and to compare its efficacy with formic acid treatment of common warts.

Efficacy and safety of intralesional MMR vaccine and Formic acid application in the treatment of common warts: a comparative study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/009041
Enrollment
60
Registered
2017-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- THOSE SUFFERING FROM COMMON WARTS

Interventions

Intervention1: INTERVENTION-MEASLES MUMPS RUBELLA VACCINE : MEASLES MUMPS RUBELLA VACCINE TO BE GIVEN INTRALESIONALLY INTO THE WART. Control Intervention1: FORMIC ACID: FORMIC ACID TO BE APPLIED TOP

Sponsors

Myfanwy Joanne Dsouza
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age above 18 years. Patients satisfying the diagnostic criteria. Common warts restricted only to the hands and feet, upto a maximum of 10 lesions. Patients willing for the intervention with a written informed consent.

Exclusion criteria

Exclusion criteria: Age more than 72 years. Patients with secondary infection of the warts. Pregnant and lactating women. Immunocompromised individuals. Individuals with chronic and systemic illnesses like Diabetes mellitus, renal diseases

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy and safety of intralesional MMR vaccine in the treatment of common warts. To compare the efficacy of intralesional MMR vaccine with that of formic acid puncture for the treatment of common warts.Timepoint: serial assessments will be made 2 weeks following each treatment option for a total of 5 assessments.—

Secondary

MeasureTime frame
To compare the efficacy of intralesional MMR vaccine with that of formic acid puncture for the treatment of common warts.Timepoint: 1st October 2015 to 31 December 2016—

Countries

India

Contacts

Public ContactMyfanwy Joanne DSouza

FATHER MULLER MEDICAL COLLEGE HOSPITAL

drgkamat@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026